Westaby D, Macdougall B R, Williams R
Hepatology. 1985 Sep-Oct;5(5):827-30. doi: 10.1002/hep.1840050520.
Long-term follow-up (median: 37 months; range: 19 to 68) of the 116 patients (56 sclerotherapy, 60 control group) entered into a controlled trial of endoscopic variceal sclerotherapy has shown a total of 18 deaths in the sclerotherapy group, including five from variceal bleeding compared with 32 deaths in the control group (p less than 0.01), of which 25 were from variceal hemorrhage (p less than 0.001). Survival as assessed by cumulative life analysis was significantly better in those treated by sclerotherapy (p less than 0.001). Both the cumulative proportion of patients rebleeding and the total number of episodes of variceal hemorrhage were also significantly less in the sclerotherapy group (p less than 0.01). Recurrence of varices was observed in 27 of 45 patients in whom variceal obliteration was initially observed at a median of 11 months (range: 2 to 27) later, although in only 12 of these did bleeding recur and was the cause of death in one.
对116例（56例接受硬化疗法，60例为对照组）纳入内镜下静脉曲张硬化疗法对照试验的患者进行长期随访（中位时间：37个月；范围：19至68个月），结果显示硬化疗法组共有18例死亡，其中5例死于静脉曲张出血，而对照组有32例死亡（p<0.01），其中25例死于静脉曲张出血（p<0.001）。通过累积生存分析评估，硬化疗法治疗的患者生存率显著更高（p<0.001）。硬化疗法组患者再出血的累积比例和静脉曲张出血的总发作次数也显著更低（p<0.01）。45例最初观察到静脉曲张闭塞的患者中有27例出现静脉曲张复发，中位时间为11个月（范围：2至27个月）后，不过其中只有12例再次出血，且有1例因出血死亡。
